The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech; GlaxoSmithKline; Janssen Oncology; Lilly; Mirati Therapeutics; Novocare; Seagen
Research Funding - Blueprint Medicines; Calithera Biosciences (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)
 
Mary Weber Redman
No Relationships to Disclose
 
Konstantin H. Dragnev
Research Funding - Amgen (Inst); Daiichi Sankyo/Astra Zeneca (Inst); G1 Therapeutics (Inst); Io Therapeutics (Inst); Lilly (Inst); Merck (Inst); Molecular Templates (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Wade Thomas Iams
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb/Pfizer; Catalyst Pharmaceuticals; Daichii Sankyo; Elevation Oncology; EMD Serono; Genentech; Guardant Health; Jazz Pharmaceuticals; Merus; Novocure; Sanofi; Tempus
 
Brian S. Henick
Honoraria - DAVA Oncology; OncLive/MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; IDEAYA Biosciences; Jazz Pharmaceuticals; Regeneron; Sorrento Therapeutics
Research Funding - Genentech/Roche (Inst); Johnson & Johnson/Janssen (Inst); NexImmune (Inst); Stand Up 2 Cancer (Inst); V Foundation (Inst)
 
Jieling Miao
No Relationships to Disclose
 
Michael Leo LeBlanc
Consulting or Advisory Role - Agios
 
Daniel R. Carrizosa
Consulting or Advisory Role - Coherus Biosciences; Curio Science; Sanofi/Regeneron; Targeted Oncology
Speakers' Bureau - Bristol Myers Squibb; OncLive/MJH Life Sciences; PER
Research Funding - Elevation Oncology (Inst); Ignyta (Inst); Merck (Inst); Takeda (Inst)
 
Roy S. Herbst
Leadership - American Association for Cancer Research; IASLC; Immunocore; Junshi Pharmaceuticals; Society for Immunotherapy of Cancer; SWOG
Stock and Other Ownership Interests - Bolt Biotherapeutics; Checkpoint Therapeutics; Immunocore; Normunity
Consulting or Advisory Role - Abbvie; AstraZeneca; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics; Checkpoint Therapeutics; Cybrexa Therapeutics; DynamiCure Biotechnology; eFFECTOR Therapeutics; EMD Serono; Genentech/Roche; Gilead/Forty Seven; HiberCell; I-Mab; Immune-Onc Therapeutics; Janssen; Johnson and Johnson; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; NextCure; NextCure; Normunity; Novartis; Ocean Biomedical; OncoCyte; Oncternal Therapeutics; Pfizer; Refactor Health; Regeneron; Revelar; Ribon Therapeutics; Sanofi; Seagen; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
Travel, Accommodations, Expenses - American Cancer Society; IASLC; SWOG
 
Charles D. Blanke
No Relationships to Disclose
 
Jhanelle E. Gray
Honoraria - AstraZeneca; Daiichi Sankyo, Inc; EMD Serono/Merck; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Merck; Merck; OncoCyte; Pfizer; Regeneron; Spectrum ODAC; Triptych Health Partners
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo/UCB Japan; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Jazz Pharmaceuticals; Merck; Merck; Pfizer; Regeneron; Spectrum Pharmaceuticals; Triptych Health Partners
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Services (Inst); Lilly (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Panbela Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Abbvie; OncoCyte; Spectrum Pharmaceuticals